v3.20.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue:        
Grant and licensing revenue $ 593,165 $ 342,487 $ 1,495,045 $ 1,043,549
Operating expenses:        
Research and development 2,790,797 3,424,141 5,573,303 6,596,388
General and administrative 1,801,674 1,860,459 5,072,222 5,208,060
Change in fair value of contingent consideration 843,000 112,000 816,000 226,290
Total operating expenses 5,435,471 5,396,600 11,461,525 12,030,738
Loss from operations (4,842,306) (5,054,113) (9,966,480) (10,987,189)
Change in fair value of warrant liability (24,363)   (1,002,073)  
Investor relations expense     (66,767)  
Interest income 56,080 124,793 108,790 275,645
Other income (expense), net 273,771 (15,585) 16,292 (7,264)
Total non-operating income (loss) 305,488 109,208 (943,758) 268,381
Net loss before income taxes (4,536,818) (4,944,905) (10,910,238) (10,718,808)
Income tax expense       (45,178)
Net loss (4,536,818) (4,944,905) (10,910,238) (10,763,986)
Net loss - non-controlling interest (82,388) (174,035) (163,702) (277,640)
Net loss attributable to Heat Biologics, Inc. $ (4,454,430) $ (4,770,870) $ (10,746,536) $ (10,486,346)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.05) $ (0.14) $ (0.15) $ (0.32)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 87,930,846 33,255,724 72,606,461 33,240,529
Comprehensive loss        
Net loss $ (4,536,818) $ (4,944,905) $ (10,910,238) $ (10,763,986)
Unrealized (loss) gain on foreign currency translation (179,510) 16,612 39,294 8,423
Total comprehensive loss (4,716,328) (4,928,293) (10,870,944) (10,755,563)
Comprehensive loss attributable to non-controlling interest (82,388) (174,035) (163,702) (277,640)
Comprehensive loss - Heat Biologics, Inc. $ (4,633,940) $ (4,754,258) $ (10,707,242) $ (10,477,923)

Source